ArticleJournal of nanobiotechnology2026
BioGate SERS Chip enables robust metabolite-oriented nanobiotechnological detection of breast cancer margins.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Accurate identification of malignant surgical margins remains a major challenge in breast cancer surgery due to the lack of rapid and molecularly specific diagnostic tools capable of operating in complex biological environments. Surface-enhanced Raman spectroscopy (SERS) holds promise for molecular detection; however, its application in tissues is limited by nonspecific macromolecular adsorption, signal instability, and biological screening effects. Here, we present the BioGate SERS Chip, a nanobiotechnological platform designed to enable robust, metabolite-oriented SERS detection by regulating molecular access to plasmonic hotspots. The chip features a hierarchical gold nanoparticle architecture that forms bioselective nanochannels, allowing low-molecular-weight metabolites to access electromagnetic hotspot regions while excluding macromolecules responsible for biofouling and signal suppression. This bioselective hotspot-gating strategy couples plasmonic field confinement with size-selective molecular transport, enabling reliable metabolite sensing directly in complex tissue environments. The BioGate platform exhibited a detection limit of 10⁻¹³ M for molecular probes and enabled reliable identification of malignant signatures in mixed cell populations containing as little as 1% tumor cells. Across spontaneous tumor models, xenograft surgeries, and intraoperative specimens from 50 breast cancer patients representing three major molecular subtypes (HER2+, TNBC, and HR+), the platform rapidly distinguished malignant from benign tissues within minutes using subtype-independent metabolic fingerprints. Integrated metabolomic and transcriptomic analyses further revealed that the characteristic Raman peaks originate from amino acid-related metabolic pathways, providing biochemical interpretability at the nano-bio interface. Together, these results establish the BioGate SERS Chip as a practical nanobiotechnology strategy for rapid metabolite-based intraoperative margin detection and demonstrate how bioengineered plasmonic architectures can enable robust SERS sensing in complex biological tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.